May 13, 2020 C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nas
May 6, 2020 Webinar: What you want and need to know about the Rare Disease Cures Accelerator – Data and Analytics Platform (May 6, 2020)
April 30, 2020 C-Path Appoints Two New Members to Board of Directors TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new
April 29, 2020 C-Path ePRO Consortium and PRO Consortium Announce COVID-19 Risk Assessment and Mitigation Strategies Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials. &n
April 28, 2020 C-Path Receives Letter of Support from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 28, 2020 — The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D
April 27, 2020 Critical Path for Parkinson’s Consortium 3DT Initiative: Early regulatory engagement to optimize paths for efficient use of digital health technologies in PD clinical trials A subset of CPP member organizations* have convened to collaborate precompetitively with the goal of optimizing the efficiency of
April 22, 2020-April 23, 2020 11th Annual Patient-Reported Outcome Consortium Workshop – Cancelled Scheduled for April 22 – 23, 2020 Sheraton Silver Spring Hotel 8777 Georgia Avenue Silver Spring, MD 20910 On March 11, 2020, th
April 21, 2020 Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplant Society Working Group
April 21, 2020 C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials Resulting novel drug development tools will support patient-focused drug development for children with asthma TUCSON
